NCT04139824View on ClinicalTrials.gov

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 22, 2020

Primary Completion Date

February 25, 2020

Study Completion Date

February 25, 2020

Conditions
GoutHyperuricemia
Interventions
DRUG

Xanthine Oxidase Inhibitor

LC350189 200mg qd

DRUG

nonsteroidal anti-inflammatory drug

Naproxen 500mg BID

Trial Locations (1)

78744

PPD, Austin

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT04139824 - The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults | Biotech Hunter | Biotech Hunter